Nottingham's R5 Pharmaceuticals to double in size20 January 2011
R5 Pharmaceuticals plans to double the size of its BioCity Nottingham operation.
New facilities will be created to R5's specification increasing the size to 16,000 square feet.
Over time, up to 30 new jobs could be created.
Work will begin on a new analytical chemistry laboratory in the spring with the second stage of construction completing in the second half of the year.
The expansion will also allow R5 to double its manufacturing capacity.
R5 develops and makes small runs of test medicines used in clinical trials.
Its analysts test the drugs and their delivery method before they are used on people.
The company, founded by managing director Paul Titley, is acknowledged as one of the leading providers of pharmaceutical dosage form development across Europe.
Mr Titley said the expansion was strategically essential for the company because its services were in high demand.
It followed a fast growth from existing clients and significant growth in new markets, most notably in the US.
Mr Titley said the expansion was a big step for a company founded little more than four years ago.
It currently employs 55 staff and this could increase to more than 80 as the company picks up new work.
R5 Pharmaceuticals was sold to Aesica Pharmaceuticals in June 2010.
Mr Titley said the investment demonstrated the company's commitment to evolving and enhancing services to meet demand.
"That we are set to double the size of our site and create new facilities, which will enable us to introduce new services to our current provision, is testament to the dedication and expertise of the entire team in establishing R5 as a leader in its field," he said.
"Aesica strives to become the leading provider of formulated products and active pharmaceutical ingredients to the global pharma and biotechnology industries."
Aesica is one of the UK's fastest growing companies and says it is currently undergoing a period of significant expansion both in the UK, Europe and America.
The R5 expansion follows Aesica's announcement last month that it had acquired three manufacturing sites in Europe, almost doubling its workforce.